Author: Yasunori Watanabe; Joel D. Allen; Daniel Wrapp; Jason S. McLellan; Max Crispin
Title: Site-specific analysis of the SARS-CoV-2 glycan shield Document date: 2020_3_28
ID: 63j4qc7d_17
Snippet: In addition to oligomannose-type glycans, the processing of complex-type glycans is an important consideration in immunogen engineering. Across the 22 N-linked glycosylation sites, 16% of the glycans contain at least one sialic acid residue and 48% are fucosylated (Figure 4) . These data suggest high levels of fucosylation but low levels of sialylation, considering complex and hybrid type glycans make up 69% of the total glycans of SARS-CoV-2. Un.....
Document: In addition to oligomannose-type glycans, the processing of complex-type glycans is an important consideration in immunogen engineering. Across the 22 N-linked glycosylation sites, 16% of the glycans contain at least one sialic acid residue and 48% are fucosylated (Figure 4) . These data suggest high levels of fucosylation but low levels of sialylation, considering complex and hybrid type glycans make up 69% of the total glycans of SARS-CoV-2. Understanding the distribution of glycan modifications across the viral spike illustrates the differential susceptibility to different processing enzymes while the absolute levels can be heavily influenced by the cellular expression system utilized. We have previously demonstrated for HIV-1 Env glycosylation that the processing of complex-type glycans is driven by the producer cell but that the levels of oligomannose-type glycans were largely independent of the expression system and is much more closely related to the protein structure and glycan density 38 .
Search related documents:
Co phrase search for related documents- high level and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77
- high level and processing enzyme: 1
- high level and protein structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- high level and sialic acid: 1, 2, 3, 4
- high level and viral spike: 1, 2, 3, 4, 5, 6, 7, 8, 9
- important consideration and protein structure: 1
- important consideration and viral spike: 1, 2
- low level and protein structure: 1, 2, 3, 4
- low level and sialylation low level: 1
- low level and viral spike: 1, 2, 3, 4, 5, 6, 7
- oligomannose type and protein structure: 1, 2
- oligomannose type and sialic acid: 1
- oligomannose type and total glycan: 1
- oligomannose type and type hybrid complex glycan: 1, 2, 3, 4
- oligomannose type and viral spike: 1, 2, 3, 4
- oligomannose type glycan and protein structure: 1
- oligomannose type glycan and total glycan: 1
- oligomannose type glycan and type hybrid complex glycan: 1, 2, 3
- oligomannose type glycan and viral spike: 1
Co phrase search for related documents, hyperlinks ordered by date